Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-08-10Clinical Trial Update: The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial examining cellular immune adjuvant therapy for triple-negative breast cancer, sponsored by First Affiliated Hospital Xi'an J…
-
CLINICAL_TRIALS withdrawal · 2016-07-26Clinical Trial Update: Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer [Phase 1]
A Phase 1 trial of talazoparib in combination with the HSP90 inhibitor AT13387 for metastatic advanced solid tumors and recurrent ovarian, f…
-
CLINICAL_TRIALS withdrawal · 2016-05-30Clinical Trial Update: A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer [NA]
A pilot preoperative trial of ganetespib with paclitaxel for triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-04-29Clinical Trial Update: Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer [Phase 2]
A Phase 2 biomarker study of PF-03084014 in chemoresistant triple-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-06-22Clinical Trial Update: Allogenic Haematopoietic Cell Transplantation for Patients With Refractory "Triple Negative" Breast Cancer [Phase 2]
A Phase 2 trial evaluating allogeneic hematopoietic cell transplantation for patients with refractory triple-negative breast cancer has been…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-04-27Clinical Trial Update: LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating LDE225 (sonidegib) for stage II-III estrogen receptor- and HER2-negative breast cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-12-19Clinical Trial Update: Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004) [Phase 2]
Phase 2 safety and efficacy trial of vintafolide (EC145) with or without paclitaxel versus paclitaxel alone in triple-negative breast cancer…
-
CLINICAL_TRIALS withdrawal · 2014-02-12Clinical Trial Update: Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery [Phase 2]
The Phase 2 trial of oral microencapsulated diindolylmethane for stage II-III triple-negative, androgen receptor-positive breast cancer afte…
-
CLINICAL_TRIALS withdrawal · 2014-02-06Clinical Trial Update: Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery [NA]
A clinical trial evaluating azacitidine for triple-negative breast cancer across stages I–IV and recurrent disease has been withdrawn (spons…
-
CLINICAL_TRIALS withdrawal · 2014-01-28Clinical Trial Update: Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer [NA]
The clinical trial evaluating vorinostat before surgery for Stage II/IIIA breast cancer, including triple-negative breast cancer, has been w…
-
CLINICAL_TRIALS withdrawal · 2012-06-26Clinical Trial Update: Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) [Phase 1]
A Phase 1 trial evaluating the maximum tolerated dose of liposomal doxorubicin in combination with seliciclib for metastatic triple-negative…